Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> DNA Damage/DNA Repair >> CDK

CDK

<div class="colum_1 clearer"><p>CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.</p><p>There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.</p><p>CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of <i>S. pombe</i> (Cdc2), <i>S. cerevisia</i> (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).</p></div>

Targets for  CDK

Products for  CDK

  1. Cat.No. Product Name Information
  2. GC33107 (±)-BAY-1251152

    (±)-BAY-1251152; (±)-VIP152

     (±)-BAY-1251152 ((±)-BAY-1251152) is a racemic mixture of BAY-1251152. BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor. (±)-BAY-1251152 Chemical Structure
  3. GC32429 (-)-BAY-1251152

    (-)-BAY-1251152; (-)-VIP152

     (-)-BAY-1251152 ((-)-BAY-1251152) is an enanthiomer of BAY-1251152 with rotation (-). BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor. (-)-BAY-1251152 Chemical Structure
  4. GC38377 (2S,3R)-Voruciclib hydrochloride (2S,3R)-Voruciclib hydrochloride is the enantiomer of Voruciclib hydrochloride. (2S,3R)-Voruciclib is an orally active CDK inhibitor. (2S,3R)-Voruciclib hydrochloride Chemical Structure
  5. GC64429 (E/Z)-Zotiraciclib citrate

    (E/Z)-TG02 citrate; (E/Z)-SB1317 citrate

     (E/Z)-Zotiraciclib citrate is a potent CDK2, JAK2, and FLT3 inhibitor. (E/Z)-Zotiraciclib citrate Chemical Structure
  6. GC63864 (E/Z)-Zotiraciclib hydrochloride

    (E/Z)-TG02 hydrochloride; (E/Z)-SB1317 hydrochloride

     (E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent CDK2, JAK2, and FLT3 inhibitor. (E/Z)-Zotiraciclib hydrochloride Chemical Structure
  7. GC74261 (R)-(+)-O-Demethylbuchenavianine (R)-(+)-O-Demetlbuchenavianine is an inhibitor for Cyclin-dependent kinases (CDK). (R)-(+)-O-Demethylbuchenavianine Chemical Structure
  8. GC41716 (R)-CR8 Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. (R)-CR8 Chemical Structure
  9. GC39281 (R)-CR8 trihydrochloride

    CR8, (R)-Isomer trihydrochloride

     (R)-CR8 (CR8) trihydrochloride, a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 trihydrochloride Chemical Structure
  10. GC34124 (rel)-MC180295

    (rel)-MC180295

     (rel)-MC180295 ((rel)-(rel)-MC180295) is a potent and selective CDK9-Cyclin T1 inhibitor, with an IC50 of 5 nM, at least 22-fold more selective for CDK9 over other CDKs. (rel)-MC180295 also inhibits GSK-3α and GSK-3β. (rel)-MC180295 ((rel)-(rel)-MC180295) has potent anti-tumor effect. (rel)-MC180295 Chemical Structure
  11. GC74262 (S)-(-)-O-Demethylbuchenavianine (S)-(-)-O-Demetlbuchenavianine (Compound (S)-(−)-1) is a flavonoidal alkaloids. (S)-(-)-O-Demethylbuchenavianine Chemical Structure
  12. GC65877 (S)-GFB-12811 (S)-GFB-12811 (compound 596) is a potent and selective CDK5 inhibitor, with an IC50 value less than 10 nM. (S)-GFB-12811 can be used in the research of cell cycle progression, neuronal development, tumorigenesis. (S)-GFB-12811 Chemical Structure
  13. GC65997 (S)-LY3177833 hydrate (S)-LY3177833 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor. (S)-LY3177833 hydrate shows broad in vitro anticancer activity. (S)-LY3177833 hydrate Chemical Structure
  14. GC64399 2,4,6-Trihydroxybenzoic acid 2,4,6-Trihydroxybenzoic acid, the flavonoid metabolite, is a CDK inhibitor. 2,4,6-Trihydroxybenzoic acid can be used for the research of cancer. 2,4,6-Trihydroxybenzoic acid Chemical Structure
  15. GC35162 5-Iodo-indirubin-3'-monoxime 5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase, with IC50s of 9, 20 and 25 nM, respectively. 5-Iodo-indirubin-3'-monoxime Chemical Structure
  16. GC60532 6-(Dimethylamino)purine 6-(Dimethylamino)purine is a dual inhibitor of protein kinase and CDK. 6-(Dimethylamino)purine Chemical Structure
  17. GC63728 Abemaciclib metabolite M18 hydrochloride

    LSN3106729 hydrochloride

     Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib, is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader. Abemaciclib metabolite M18 hydrochloride Chemical Structure
  18. GC38749 Abemaciclib metabolite M20

    LSN3106726

     Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4/6 inhibitor for the treatment of cancer. Abemaciclib metabolite M20 Chemical Structure
  19. GC35218 Abemaciclib Metabolites M2

    LSN2839567

     Abemaciclib Metabolites M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50s of 1.2 and 1.3 nM, respectively. Anti-cancer activity. Abemaciclib Metabolites M2 Chemical Structure
  20. GC64280 Abemaciclib-d8

    LY2835219-d8

     Abemaciclib-d8 (LY2835219-d8) is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively. Abemaciclib-d8 Chemical Structure
  21. GC71063 Akt1&PKA-IN-1 Akt1&PKA-IN-1 is a potent dual Akt/PKA inhibitor with IC50 values of 0.03 , 0.11 μM, and 9.8 μM for PKAa, Akt, and CDK2, respectively. Akt1&PKA-IN-1 Chemical Structure
  22. GC15841 Alsterpaullone

    9-Nitropaullone,NSC 705701

     CDKs and GSK3β inhibitor Alsterpaullone Chemical Structure
  23. GC14974 AMG 925 FLT3/CDK4 inhibitor,potent and selective AMG 925 Chemical Structure
  24. GC35315 AMG 925 HCl AMG 925 HCl is a potent, selective, and orally available FLT3/CDK4 dual inhibitor with IC50s of 2±1 nM and 3±1 nM, respectively. AMG 925 HCl Chemical Structure
  25. GC38736 AS2863619 A dual inhibitor of Cdk8 and Cdk19 AS2863619 Chemical Structure
  26. GC38737 AS2863619 free base AS2863619 free base enables conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells for the treatment of various immunological diseases. AS2863619 free base Chemical Structure
  27. GC15870 AT7519 Multi-CDK inhibitor AT7519 Chemical Structure
  28. GC13998 AT7519 Hydrochloride A Cdk inhibitor AT7519 Hydrochloride Chemical Structure
  29. GC15597 AT7519 trifluoroacetate AT7519 trifluoroacetate Chemical Structure
  30. GC34422 Atuveciclib (BAY-1143572) Atuveciclib (BAY-1143572) Chemical Structure
  31. GC34059 Atuveciclib Racemate (BAY-1143572 Racemate)

    BAY-1143572 Racemate

     Atuveciclib Racemate (BAY-1143572 Racemate) (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib. Atuveciclib is a potent and highly selective, oral P-TEFb/CDK9 inhibitor which supresses CDK9/CycT1 with an IC50 of 13 nM. Atuveciclib Racemate (BAY-1143572 Racemate) Chemical Structure
  32. GC34421 Atuveciclib S-Enantiomer (BAY-1143572 S-Enantiomer) Atuveciclib S-Enantiomer (BAY-1143572 S-Enantiomer) Chemical Structure
  33. GC63449 Avotaciclib

    BEY1107

     Avotaciclib (BEY1107) is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). Avotaciclib can be used for the research of locally advanced or metastatic pancreatic cancer. Avotaciclib Chemical Structure
  34. GC68712 AZ5576

    AZ5576 is a potent and highly selective inhibitor of CDK9 (IC50: <5 nM). It can be used for research on hematologic malignancies.

     AZ5576 Chemical Structure
  35. GC12438 AZD-5438

    AZD 5438;AZD5438

     Potent CDK1/2/9 inhibitor AZD-5438 Chemical Structure
  36. GC32717 AZD4573 AZD4573 is a potent and highly selective CDK9 inhibitor (IC50 of <4 nM) that enables transient target engagement for the treatment of hematologic malignancies. AZD4573 Chemical Structure
  37. GC73787 AZD8421 AZD8421 is a selective CDK2 inhibitor (IC50: 9 nM) with selectivity for CDK1, CDK4 and CDK6. AZD8421 Chemical Structure
  38. GC19067 BGG463

    K03859

     BGG463 is a CDK2 inhibitor. BGG463 Chemical Structure
  39. GC35512 BI-1347 BI-1347 is an orally active, selective and potent CDK8 inhibitor (IC50=1.1 nM). BI-1347 shows anti-tumoral activity. BI-1347 Chemical Structure
  40. GC62653 bio-THZ1 bio-THZ1 is a biotinylated version of THZ1 and binds irreversibly to CDK7. THZ1 is a selective and potent covalent CDK7 inhibitor with an IC50 of 3.2 nM. bio-THZ1 Chemical Structure
  41. GC18354 Bisindolylmaleimide X (hydrochloride)

    BIM X, Ro 31-8425

     Bisindolylmaleimide X is a cell-permeable, reversible, ATP-competitive protein kinase C (PKC) inhibitor (IC50 = 15 nM, rat brain PKC). Bisindolylmaleimide X (hydrochloride) Chemical Structure
  42. GC73893 BLU-222 BLU-222 is an orally active and highly selective CDK2 inhibitor. BLU-222 Chemical Structure
  43. GC12865 BMS265246 CDK1/2 inhibitor,potent and selective BMS265246 Chemical Structure
  44. GC11040 Borrelidin

    NSC 216128, Treponemycin

     threonyl-tRNA synthetase (ThrRS) inhibitor Borrelidin Chemical Structure
  45. GC50452 BRD 6989 Cdk8 inhibitor; enhances IL-10 production BRD 6989 Chemical Structure
  46. GC50217 BS 181 dihydrochloride Selective cdk7 inhibitor BS 181 dihydrochloride Chemical Structure
  47. GC12001 BS-181 A selective Cdk7 inhibitor BS-181 Chemical Structure
  48. GC13690 BS-181 HCl BS-181 HCl is a highly selective CDK7 inhibitor with IC50 of 21 nM, and > 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9. BS-181 HCl Chemical Structure
  49. GC65128 BSJ-03-123 BSJ-03-123 is a PROTAC connected by ligands for Cereblon and CDK as a potent and novel CDK6-selective small-molecule degrader. BSJ-03-123 Chemical Structure
  50. GC50615 BSJ-03-204 Selective Cdk4/6 degrader BSJ-03-204 Chemical Structure
  51. GC73053 BSJ-03-204 triTFA BSJ-03-204 triTFA is a PROTAC connected by ligands for Cereblon and CDK. BSJ-03-204 triTFA Chemical Structure
  52. GC62263 BSJ-4-116 BSJ-4-116 is a PROTAC connected by ligands for Cereblon and CDK. BSJ-4-116 is a highly potent and selective CDK12 degrader (PROTAC) with an IC50 of 6 nM. BSJ-4-116 downregulates DDR genes through a premature termination of transcription, primarily through increasing poly(adenylation). BSJ-4-116 exhibits potent antiproliferative effects, alone and in combination with the poly(ADP-ribose) polymerase inhibitor Olaparib. BSJ-4-116 Chemical Structure
  53. GC30977 Ca2+ channel agonist 1 Ca2+ channel agonist 1 is an agonist of N-type Ca2+ channel and an inhibitor of Cdk2, with EC50s of 14.23 μM and 3.34 μM, respectively, and is used as a potential treatment for motor nerve terminal dysfunction. Ca2+ channel agonist 1 Chemical Structure
  54. GC62442 Casein Kinase inhibitor A51 Casein Kinase inhibitor A51 is a potent and orally active casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A51 induces leukemia cell apoptosis, and has potent anti-leukemic activities. Casein Kinase inhibitor A51 Chemical Structure
  55. GC43175 CAY10574 CAY10574 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. CAY10574 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity. CAY10574 Chemical Structure
  56. GC19089 CC-671 CC-671 is a dual TTK protein kinase/CDC2-like kinase (CLK2) inhibitor with IC50s of 0.005 and 0.006 uM for TTK and CLK2, respectively. CC-671 Chemical Structure
  57. GC32741 CCT-251921 CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor with an IC50 of 2.3 nM. CCT-251921 Chemical Structure
  58. GC35628 Cdc7-IN-1 Cdc7-IN-1 (Compound 13) is a highly potent, selective and ATP competitive inhibitor of Cdc7 kinase, with an IC50 value of 0.6 nM at 1 mM ATP and with slow off-rate characteristics. Cdc7-IN-1 potently inhibits Cdc7 activity in cancer cells, and effectively induces cell death. Cdc7-IN-1 Chemical Structure
  59. GC62427 Cdc7-IN-5 Cdc7-IN-5 (compound I-B) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-B. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle. Cdc7-IN-5 Chemical Structure
  60. GC73970 CDDD11-8 CDDD11-8 is an orally active, potent and selective inhibitor of CDK9 and FLT3-ITD, with Ki values of 8 and 13 nM, respectively. CDDD11-8 Chemical Structure
  61. GC12425 CDK inhibitor II

    CDK inhibitorII

     CDK inhibitor II Chemical Structure
  62. GC38899 CDK ligand for PROTAC hydrochloride CDK ligand for PROTAC hydrochloride Chemical Structure
  63. GC62168 CDK-IN-6 CDK-IN-6, a class of pyrazolo[1,5-a]pyrimidine compound, is a CDK inhibitor with anticancer activities. CDK-IN-6 Chemical Structure
  64. GC68846 CDK1-IN-2

    CDK1-IN-2 is a CDK1 inhibitor (IC50: 5.8 μM).

     CDK1-IN-2 Chemical Structure
  65. GC63499 CDK12-IN-2

    CDK12-IN-2 is a potent, selective and nanomolar CDK12 inhibitor (IC50=52 nM) with good physicochemical properties.

     CDK12-IN-2 Chemical Structure
  66. GC68845 CDK12-IN-5

    CDK12-IN-5 is a pyrazole-triazine compound that is an effective inhibitor of CDK12, with an IC50 of 23.9 nM at high ATP (2 mM). CDK12-IN-5 has no effect on CDK2/Cyclin E (IC50=173 μM) and CDK9/Cyclin T1 (IC50=127 μM) at high ATP (2 mM) (WO2021116178A1).

     CDK12-IN-5 Chemical Structure
  67. GC68847 CDK2-IN-13

    CDK2-IN-13 (Compound 15) is a CDK2 inhibitor with an IC50 value of 12 μM. CDK2-IN-13 can be used for cancer research.

     CDK2-IN-13 Chemical Structure
  68. GC73976 CDK2-IN-23 CDK2-IN-23 (Compound 17) is a kinase selective and highly potent CDK2 inhibitor (IC50 = 0.29 nM). CDK2-IN-23 Chemical Structure
  69. GC35632 CDK2-IN-4 CDK2-IN-4 is a potent and selective CDK2 inhibitor with an IC50 of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (IC50=86 uM). CDK2-IN-4 Chemical Structure
  70. GC65190 CDK4/6-IN-11 CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader. CDK4/6-IN-11 Chemical Structure
  71. GC68848 CDK4/6-IN-15

    CDK4/6-IN-15 is an orally effective and selective CDK4/6 inhibitor. It can effectively inhibit cancer cell growth. CDK4/6-IN-15 blocks the cell cycle in the G1 phase and inhibits phosphorylation of retinoblastoma tumor suppressor protein (Rb) at S780 site and E2 factor (E2F)-regulated gene expression in retinoblastoma tumors.

     CDK4/6-IN-15 Chemical Structure
  72. GC73086 CDK4/6-IN-15 hydrochloride CDK4/6-IN-15 drochloride is an orally active and selective CDK4/6 inhibitor. CDK4/6-IN-15 hydrochloride Chemical Structure
  73. GC35633 CDK4/6-IN-2 CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor extracted from patent US20180000819A1, Compound 1, has IC50s of 2.7 and 16 nM for CDK4 and CDK6, respectively. CDK4/6-IN-2 Chemical Structure
  74. GC35634 CDK4/6-IN-3 CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor with Kis of <0.3 nM and 2.2 nM, respectively. CDK4/6-IN-3 inhibits CDK1 with a Ki of 110 nM. CDK4/6-IN-3 can be used for the treatment of glioblastoma. CDK4/6-IN-3 Chemical Structure
  75. GC64802 CDK4/6-IN-6

    CDK4/6-IN-6

     CDK4/6-IN-6 (example A94) is a potent CDK4/CDK6 inhibitor with a Ki of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively. CDK4/6-IN-6 Chemical Structure
  76. GC60680 CDK5 inhibitor 20-223 CDK5 inhibitor 20-223 is a potent CDK2 and CDK5 inhibitor with IC50s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agent. CDK5 inhibitor 20-223 Chemical Structure
  77. GC66009 CDK5-IN-3 CDK5-IN-3 (compound 11) is a potent and selective CDK5 inhibitor, with IC50s of 0.6 nM and 18 nM for CDK5/p25 and CDK2/CycA, respectively. CDK5-IN-3 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD). CDK5-IN-3 Chemical Structure
  78. GC74324 Cdk5i peptide Cdk5i peptide is a 12-amino acid peptide fragment derived from Cdk5. Cdk5i peptide Chemical Structure
  79. GC63980 CDK7-IN-2 CDK7-IN-2 is a potent inhibitor of CDK7. CDK7 is implicated in both temporal control of the cell cycle and transcriptional activity. CDK7 is implicated in the transcriptional initiation process by phosphorylation of Rbpl subunit of RNA Polymerase II (RNAPII). CDK7 has the potential for the research of cancer disease, in particular aggressive and hard- to-treat cancers (extracted from patent WO2019099298A1, compound 1). CDK7-IN-2 Chemical Structure
  80. GC73429 CDK7-IN-21 CDK7-IN-21 (compound A22) is a potent CDK7 inhibitor. CDK7-IN-21 Chemical Structure
  81. GC62596 CDK7-IN-3 CDK7-IN-3 (CDK7-IN-3) is an orally active, highly selective, noncovalent CDK7 inhibitor with a KD of 0.065 nM. CDK7-IN-3 shows poor inhibition on CDK2 (Ki=2600 nM), CDK9 (Ki=960 nM), CDK12 (Ki=870 nM). CDK7-IN-3 induces apoptosis in tumor cells and has antitumor activity. CDK7-IN-3 Chemical Structure
  82. GC65434 CDK7/12-IN-1 CDK7/12-IN-1 is a selective CDK7/12 inhibitor with IC50s of 3 and 277 nM for CDK7 and CDK 12, respectively. CDK7 and CDK12 inhibition is an effective strategy to inhibit tumour growth. CDK7/12-IN-1 Chemical Structure
  83. GC60681 CDK7/9 tide CDK7/9 tide is peptide substrate for CDK7 or CDK9. CDK7/9 tide Chemical Structure
  84. GC33180 CDK8-IN-1 CDK8-IN-1 is a potent and selective CDK8 inhibitor with an IC50 of 3 nM. CDK8-IN-1 Chemical Structure
  85. GC73345 CDK8-IN-11 CDK8-IN-11 is a potent and selective CDK8 inhibitor with an IC50 value of 46 nM. CDK8-IN-11 Chemical Structure
  86. GC73183 CDK8-IN-12 CDK8-IN-12 is an orally active, potent CDK8 inhibitor with a Ki of 14 nM. CDK8-IN-12 Chemical Structure
  87. GC73288 CDK8-IN-13 CDK8-IN-13 is a potent, selective and orally active CDK8 inhibitor with an IC50 value of 51.9 nM. CDK8-IN-13 Chemical Structure
  88. GC30466 CDK8-IN-3 CDK8-IN-3 is an inhibitor of CDK8 extracted from patent WO2016041618A1, compound example 1.7. CDK8-IN-3 Chemical Structure
  89. GC33366 CDK8-IN-4 CDK8-IN-4 is an inhibitor of CDK8 extracted from patent WO2014090692A1, compound example 16, with an IC50 of 0.2 nM. CDK8-IN-4 Chemical Structure
  90. GC35635 CDK9 Antagonist-1 CDK9 Antagonist-1 Chemical Structure
  91. GC12871 CDK9 inhibitor CDK9 inhibitor Chemical Structure
  92. GC17359 CDK9 inhibitor 2 CDK9 inhibitor 2 Chemical Structure
  93. GC72951 CDK9 inhibitor HH1 CDK9 inhibitor HH1 is a potent and selectively CDK9 inhibitor. CDK9 inhibitor HH1 Chemical Structure
  94. GC66475 CDK9-IN-10 CDK9-IN-10 is a potent CDK9 inhibitor. CDK9-IN-10 is the ligand for the PROTAC CDK9 degrader-2 (HY-112811). CDK9-IN-10 Chemical Structure
  95. GC65262 CDK9-IN-13 CDK9-IN-13 (compound 38) is potent and selective CDK9 inhibitor, with an IC50 of <3 nM. CDK9-IN-13 exhibits short half-lives in rodents. CDK9-IN-13 Chemical Structure
  96. GC64446 CDK9-IN-15 CDK9-IN-15 (compound 50) is a potent CDK9 inhibitor. CDK9-IN-15 Chemical Structure
  97. GC35636 CDK9-IN-7 CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC. CDK9-IN-7 Chemical Structure
  98. GC65247 CDK9-IN-8 CDK9-IN-8 is a highly effective and selective CDK9 inhibitor with an IC50 of 12 nM. CDK9-IN-8 Chemical Structure
  99. GC19096 CDKI-73

    LS-007

     CDKI-73 is a potent CDK9 inhibitor with Ki of 4 nM; shows selective toxicity to CLL cells(LD50=80 nM) versus normal B cell and normal CD34+ cell(LD50>20 uM). CDKI-73 Chemical Structure
  100. GC65878 Cimpuciclib tosylate Cimpuciclib tosylate is a selective CDK4 inhibitor (IC50: 0.49 nM) that has anti-tumor activity. Cimpuciclib tosylate Chemical Structure
  101. GC63476 Cirtuvivint

    SM08502

     Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research. Cirtuvivint Chemical Structure

Items 1 to 100 of 268 total

per page
  1. 1
  2. 2
  3. 3

Set Descending Direction